Phase I/IB study of polyadenylic-polyuridylic acid in patients with advanced malignancies: Clinical and biologic effects

Journal of Interferon and Cytokine Research

Volumn 16, Issue 8, 1996, Pages 631-635

  Witt, Patricia L ^a,c   Zahir, S ^a   Ritch, Paul S ^a   McAuliffe, Timothy M ^a   Ewel, Cynthia H ^b   Borden, Ernest C ^a,d  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Henri Beaufour Institute   (United States)

^c Stephens College   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; BETA 2 MICROGLOBULIN; BIOLOGICAL RESPONSE MODIFIER; CYTOKINE; NEOPTERIN; POLYADENYLIC POLYURIDYLIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FATIGUE; FEMALE; FEVER; HUMAN; HYPERGLYCEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

MURINAE;

EID: 0029844046     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1996.16.631     Document Type: Article

References (27)

1. MEMET, S., BESANCON, F., BOURGEADE, M.-F., and THANG, M.N. (1991). Direct induction of interferon-γ and interferon-αβ-inducible genes by double stranded RNA. J. Interferon Res. 11, 131-141.
2. USHIJIMA, H., RYTIK, P.G., SCHACKE, H., SCHEFFER, U., MULLER, W.E.G., and SCHROEDER, H.C. (1993). Mode of action of the anti-AIDS compound poly(I) poly(C12U) (Ampligen): activator of 2′,5′-oligoadenylate synthetase and double-stranded RNA-dependent kinase. J. Interferon Res. 13, 161-171.
3. LEVY, H.B. (1985). Historical overview of the use of polynucleotides in cancer. J. Biol. Response Mod. 4, 475-480.
4. WITT, P.L. (1995). Chemically defined immunomodulators and interferon inducers. In: Biologic Therapy of Cancer, 2nd ed. V. T. J. DeVita, S. Hellman, and S. A. Rosenberg (eds.) Philadelphia: J.B. Lippincott Co., pp. 787-794.
5. TANG, K.F., TS'O, P.O., and LESKO, S.A. (1989). Production of interferon-beta upon induction with polyinosinic acid:polycytidylic acid during the cell cycle of human fibroblasts. Exp. Cell Res. 181, 432-441.
6. HERTZOG, P.J., CHEETHAM, B.F., SEXTON, J.L., and LINNANE, A.W. (1989). Characterization of interferons produced by peripheral blood mononuclear cells from health subjects in response to Corynebacterium parvum or polyI:polyC. Biochem. Int. 19, 1427-1436.
7. FLEIT, H.B., and RABINOVITCH, M. (1981). Production of interferon by in vitro derived bone marrow macrophages. Cell. Immunol. 57, 495-504.
8. FIBBE, W.E., DAHA, M.R., HIEMSTRA, P.S., DUINKERKEN, N., LUVINK, E., RALPH, P., ALTROCK, B.W., KAUSHANSKY, K., WILLEMZE, R., and FALKENBURG, J.H. (1989). Interleukin 1 and poly(rI):poly(rC) induce production of granulocyte CSF, macrophage CSF, and granulocyte-macrophage CSF by human endothelial cells. Exp. Hematol. 17, 229-234.
9. GARFINKEL, S., HAINES, D.S., BROWN, S., WESSENDORF, J., GILLESPIE, D.H., and MACIAG, T. (1992). Interleukin-1 alpha mediates an alternative pathway for the antiproliferative action of poly(I.C) on human endothelial cells. J. Biol. Chem. 267, 24375-24378.
10. COHEN, S.A., TZUNG, S.P., DOERR, R.J., and GOLDROSEN, M.H. (1990). Role of asialo-GM1 positive liver cells from athymic nude or polyinosinic-polycytidylic acid-treated mice in suppressing colon derived experimental hepatic metastasis. Cancer Res. 50, 1834-1840.
11. NORTH, R.J., DUNN, P.L., and HAVELL, E.A. (1991). A role for tumor necrosis factor in poly(I:C)-induced hemorrhagic necrosis and T-cell-dependent regression of a murine sarcoma. J. Interferon Res. 11, 333-340.
12. LEVINE, A.S., DURIE, B., LAMPKIN, B., LEVENTHAL, B.G., and LEVY, H.B. (1981). Poly(ICLC): interferon induction, toxicity and clinical efficacy in leukemia, lymphoma, solid tumors, myeloma and laryngeal papillomatosis. In: Augmenting Agents in Cancer Therapy. E. M. Hersh, M. A. Chirigos, and M. J. Mastrangelo (eds.). New York: Raven Press, pp. 151-163.
13. BEVER, C.T., McFARLAND, H.F., McFARLIN, D.E., and LEVY, H.B. (1988). The kinetics of interferon induction by poly ICLC in humans. J. Interferon Res. 8, 419-425.
14. LAMPKIN, B.C., LEVINE, A.S., LEVY, H., KRIVIT, W., and HAMMOND, D. (1985). Phase II trial of a complex polyriboinosinic-polyribocytidylic acid with poly-L-lysine and carboxymethyl cellulose in the treatment of children with acute leukemia and neuroblastoma: a report from the Children's Cancer Study Group. Cancer Res. 45, 5904-5909.
15. KROWN, S.E., KERR, D., STEWART, W.E.I.I., POLLACK, M.S., CUNNINGHAM-RUNDLES, S., HIRSHAUT, Y., PINSKY, C.M., LEVY, H.B., and OETTGEN, H.F. (1981). Phase I trial of poly ICLC in patients with advanced cancer. In: Augmenting Agents in Cancer Therapy. E. M. Hersh, M. A. Chirigos, and M. J. Mastrangelo (eds). New York: Raven Press, pp. 165-176.
16. MALUISH, A.E., REID, J.W., CRISP, E.A., OVERTON, W.R., LEVY, H., FOON, K.A., and HERBERMAN, R.B. (1985). Immunomodulatory effects of poly(I,C)-LC in cancer patients. J. Biol. Response Mod. 4, 656-663.
17. EWEL, C.H., URBA, W.J., KOPP, W.C., SMITH, J.W.I.I., STEIS, R.G., ROSSIO, J.L., LONGO, D.L., JONES, M.J., ALVORD, W.G., PINSKY, C.M., BEVERIDGE, J.M., McNITT, K.L., and CREEKMORE, S.P. (1992). Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects. Cancer Res. 52, 3005-3010.
18. RIVIERE, Y., and HOVANESSIAN, A.G. (1983). Direct action of interferon and inducers of interferon on tumor cells in athymic nude mice. Cancer Res. 43, 4596-4599.
19. RIVIERE, Y., and HOVANESSIAN, A.G. (1984). Antitumor action of interferon and poly(a)poly(U) on HeLa xenografts in the nude mouse. Ann. Immunol. Inst. Pasteur 135C, 333-343.
20. YOUN, J.K., HOVANESSIAN, A.G., RIVIERE, Y., HUE, G., and LACOUR, F. (1983). Enhancement of natural killer cell activity and 2-5A synthetase in mice treated with polyadenylic.polyuridylic acid. Cell. Immunol. 79, 298-308.
21. LACOUR, F., SPIRA, A., LACOUR, J., and PRADE, M. (1972). Polyadenylic-polyuridylic acid, an adjunct to surgery in the treatment of spontaneous mammary tumors in C3H-He mice and transplantable melanoma in the hamsler. Cancer Res. 32, 648-649.
22. LACOUR, J., LACOUR, F., SPIRA, A., MICHELSON, M., PETIT, J.-Y., DELAGE, G., SARRAZIN, D., CONTESSO, G., and VIGUIER, J. (1984). Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer: updated results of a randomized trial. Br. Med. J. 288, 589-592.
23. LACOUR, J., LAPLANCHE, A., DELOZIER, T., BERLIE, J., MOURALI, N., JULIEN, J.P., DEGISLAIN, C., NAMER, M., PETIT, J.C., DENIS, V., and LUBOINSKI, M. (1991). Polyadenylic-polyuridylic acid plus locoregional and pelvic radiotherapy versus chemotherapy with CMF as adjuvants in operable breast cancer. Breast Cancer Res. Treat. 19, 15-21.
24. YOUN, J.K., KIM, B.S., MIN, J.S., LEE, K.S., CHOI, H.J., LEE, Y.B., LEE, D.W., PARK, I.S., ROH, J.K., CHUNG, J.B., KOH, E.H., PARK, Y.J., KIM, H.I., and LEE, K.B. (1990). Adjuvant treatment of operable stomach cancer with polyadenylic.polyuridylic acid in addition to chemotherapeutic agents: a preliminary report. Int. J. Immunopharmacol. 12, 289-295.
25. WITT, P.L., SPEAR, G.T., HELGESON, D.O., LINDSTROM, M.J., SMALLEY, R.V., and BORDEN, E.C. (1990). Basal and interferon-induced 2′5′-oligoadenylate synthetase in human monocytes, lymphocytes and peritoneal macrophages. J. Interferon Res. 10, 393-402.
26. HOVANESSIAN, A.G., YOUN, J.K., BUFFET-JANVRESSE, C., RIVIERE, Y., MICHELSON, M., LACOUR, J., and LACOUR, F. (1985). Enhancement of natural killer cell activity and 2-5A synthetase in operable breast cancer patients treated with polyadenylic.polyuridylic acid. Cancer 55, 357-362.
27. KHAN, A.L., RICHARDSON, S., DREW, J., LARSEN, F., CAMPBELL, M., HEYS, S.D., AH-SEE, A.K., and EREMIN, O. (1995). Polyadenylic-polyuridylic acid enhances the natural cell mediated cytotoxicity in patients with breast cancer undergoing mastectomy. Surgery 118, 531-538.